Funds advised by CapVest Partners LLP (“CapVest”) have signed a definitive agreement to acquire NextPharma, a leading pharmaceutical contract development and manufacturing organisation (CDMO), from an affiliate of Sun European Partners, LLP (“Sun”). The proposed transaction is subject to customary regulatory approvals.
NextPharma is a market leader within the European pharmaceutical CDMO space, serving a global bluechip customer base, including seven of the top ten pharma companies. The company offers a broad range of specialised product types and therapeutic areas across multiple attractive niches. NextPharma has over 1,000 employees and operations in Germany, France, Switzerland and Austria. CapVest is a leading London-based private equity firm and is committed to further enhancing NextPharma’s focus on patient care through its production and supply of the highest quality medicines from its state-of-the-art European production facilities.
Liberty were appointed by NextPharma CEO, Peter Burema, to advise the management team on their incentive package.
Peter Burema, CEO of NextPharma said: “Over the years, Sun and NextPharma have enjoyed an enormously successful partnership; bringing about substantial growth and development to the company and delivering a superior service to our customers around the world. The strategies implemented have put NextPharma in a much stronger position and management look forward to partnering with CapVest in building on our core values of quality, speed and service, and further expanding our customer offering.”